- Home
- BEAM vs ENLT Comparison
BEAM vs ENLT Comparison
Compare BEAM & ENLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BEAM
- ENLT
- Stock Information
- Founded
- BEAM 2017
- ENLT 2008
- Country
- BEAM United States
- ENLT Israel
- Employees
- BEAM N/A
- ENLT N/A
- Industry
- BEAM Biotechnology: Biological Products (No Diagnostic Substances)
- ENLT
- Sector
- BEAM Health Care
- ENLT
- Exchange
- BEAM Nasdaq
- ENLT Nasdaq
- Market Cap
- BEAM 1.6B
- ENLT 2.0B
- IPO Year
- BEAM 2020
- ENLT 2023
- Fundamental
- Price
- BEAM $17.23
- ENLT $22.89
- Analyst Decision
- BEAM Strong Buy
- ENLT Buy
- Analyst Count
- BEAM 11
- ENLT 3
- Target Price
- BEAM $48.90
- ENLT $19.67
- AVG Volume (30 Days)
- BEAM 1.9M
- ENLT 39.3K
- Earning Date
- BEAM 08-05-2025
- ENLT 08-06-2025
- Dividend Yield
- BEAM N/A
- ENLT N/A
- EPS Growth
- BEAM N/A
- ENLT 90.47
- EPS
- BEAM N/A
- ENLT 0.98
- Revenue
- BEAM $63,578,000.00
- ENLT $397,296,000.00
- Revenue This Year
- BEAM N/A
- ENLT $355.90
- Revenue Next Year
- BEAM $8.82
- ENLT $42.83
- P/E Ratio
- BEAM N/A
- ENLT $23.31
- Revenue Growth
- BEAM N/A
- ENLT 44.42
- 52 Week Low
- BEAM $13.53
- ENLT $14.01
- 52 Week High
- BEAM $35.25
- ENLT $23.88
- Technical
- Relative Strength Index (RSI)
- BEAM 48.68
- ENLT 77.00
- Support Level
- BEAM $16.11
- ENLT $18.22
- Resistance Level
- BEAM $17.38
- ENLT $23.60
- Average True Range (ATR)
- BEAM 1.02
- ENLT 0.50
- MACD
- BEAM 0.03
- ENLT 0.35
- Stochastic Oscillator
- BEAM 30.84
- ENLT 95.35
About BEAM Beam Therapeutics Inc.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.
About ENLT Enlight Renewable Energy Ltd.
Enlight Renewable Energy Ltd develops, finances, constructs, owns, and operates utility-scale renewable energy projects. The company's operating segments are the MENA segment, Europe segment, U.S.A segment, and Others. It generates the majority of its revenue from the Europe segment, which produces its revenue from the sale of the electricity that is produced through wind energy and solar energy in Europe.